ATLN

Insider Trades

Name	Value	Action	Price	Current Price
Broderick ChristopherChief Financial Officer $58577.2k shares BuyJan 7, 2025 $0.0001 --
Broderick ChristopherChief Financial Officer $58577.2k shares BuyJan 7, 2025 $0.0001 --
Tenore MichaelGeneral Counsel $58577.2k shares BuyJan 7, 2025 $0.0001 --
Tenore MichaelGeneral Counsel $58577.2k shares BuyJan 7, 2025 $0.0001 --
Jagid Jeffrey MDirector, Officer: Chief Executive Officer $2892.9M shares BuyJan 2, 2025 $0.0001 --
Jones Daniel RobertFormer CEO $8.6k1.5k shares BuyAug 30, 2024 $5.90 --

News

globenewswire.comAtlantic International Corp Receives Notification from Nasdaq Regarding Late Filing of Form 10-Qglobenewswire.comJun 2

globenewswire.comAtlantic International's Circle8 Group Secures $380 Million Four-Year Technology Services Contract with Dutch Ministry of Education, Culture, and Scienceglobenewswire.comMay 6

globenewswire.comAtlantic International's Circle8 Recognized as One of the Fastest-Growing IT and Technology Solutions Platforms in the Netherlandsglobenewswire.comApr 30

globenewswire.comAtlantic International Expands its $1.2 Billion Revenue (Unaudited) Platform into AI, Cybersecurity, and Data Infrastructure Through Circle8globenewswire.comApr 28

globenewswire.comAtlantic International Reports Fourth Quarter and Full Year 2025 Resultsglobenewswire.comApr 16

Trade ATLN

About Atlantic International Corp.

Based in Billerica, Massachusetts, and established in 2013, Atlantic International Corp. (which operated as SeqLL Inc. until its name change in June 2024) underwent a significant corporate change on June 18, 2024, when it was acquired by Lyneer Investments, LLC, via a reverse merger. The company operates within the life sciences sector, providing specialized instrumentation and research services. Its primary focus is on generating innovative scientific assets and proprietary intellectual property across various "omics" disciplines. Central to its offerings is the True Single Molecule Sequencing (tSMS) platform. This advanced technology provides a unique single-molecule approach to DNA and RNA sequencing by directly detecting nucleic acids. It empowers researchers to analyze billions of individual molecules within a single experiment, ensuring the generation of highly accurate and reproducible data. Atlantic International's sophisticated solutions cater to diverse applications, including biomarker discovery and the development of diagnostic assays. Its clientele spans academic institutions (such as universities), governmental research centers, and leading companies in the biotechnology and pharmaceutical industries. The company also fosters key collaborations, including an R&D agreement with the U.S. Department of Justice's Federal Bureau of Investigation to assess the forensic potential of direct RNA sequencing using its tSMS platform, and a partnership with the Weizmann Institute of Science to advance and implement cutting-edge single-molecule technologies.

CEO: Jeffrey Jagid
IPO Date: Aug 27, 2021

Market Data

Open: $0.5611
High: $0.718
Low: $0.51
Volume: 1.4M
Avg Volume: 470.9K
52W High: $5.25
52W Low: $0.51

Valuation

Market Cap: $42M
Enterprise Value: $130M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-4.5M
Revenue: $436M
Net Income: $-59M
Cash: $81k
Debt: $88M

Events

EarningsAug 13

EPS est. -0.17